FDA approves sterile blood-plasma product
SILVER SPRING, Md. — The Food and Drug Administraiton has approved a treatment for replacing clotting proteins in the blood for conditions in which patients have too little of them.
The FDA announced the approval of Octapharma’s Octaplas, a sterile, frozen solution of pooled human plasma from multiple donors that has been treated with a solvent detergent process.
"For patients suffering with clotting disorders, this product provides a viable alternative to single-donor fresh-frozen plasma and provides a reduced risk of certain viral transmissions," FDA Center for Biologics Evaluation and Research director Karen Midthun said.
Report finds ‘innovative and robust’ global drug pipeline
WASHINGTON — More than 5,000 medicines are under development, of which 70% are potentially the first of their class, according to a new report.
The Pharmaceutical Research and Manufacturers of America announced Thursday the release of a report developed by the Analysis Group that called the drug pipeline "innovative and robust." The pipeline includes 158 drugs under development for ovarian cancer, 19 for sickle cell disease and 41 for small-cell numb cancer.
"Biopharmaceutical companies, working with other partners in the American research ecosystem, have made incredible progress in helping confront some of the most challenging and costly diseases facing patients around the world," PhRMA president and CEO John Castellani said. "With more than 5,000 medicines in development for patients suffering from a wide range of diseases, there is a palpable excitement around the biopharmaceutical pipeline and the future opportunities for new, cutting-edge medicines to improve patient care and bring value to the entire U.S. healthcare system."
The report also noted that personalized medicines accounted for an increasing proportion of the pipeline, with the number of potential new medicines for rare diseases averaging 140 per year in the last 10 years, compared with 64 per year in the previous decade.
FDA approves Flublok, a trivalent influenza vaccine not made with eggs
SILVER SPRING, Md. — The Food and Drug Administration on Wednesday approved Protein Sciences’ Flublok, the first trivalent influenza vaccine made using an insect virus (baculovirus) expression system and recombinant DNA technology.
“This approval represents a technological advance in the manufacturing of an influenza vaccine,” stated Karen Midthun, director of the FDA’s Center for Biologics Evaluation and Research. “The new technology offers the potential for faster startup of the vaccine manufacturing process in the event of a pandemic, because it is not dependent on an egg supply or on availability of the influenza virus.”
Unlike current flu vaccines, Flublok does not use the influenza virus or eggs in its production. Flublok’s novel manufacturing technology allows for production of large quantities of the influenza virus protein, hemagglutinin — the active ingredient in all inactivated influenza vaccines that is essential for entry of the virus into cells in the body. The majority of antibodies that prevent influenza virus infection are directed against HA. While the technology is new to flu vaccine production, it is used to make vaccines that have been approved by the FDA to prevent other infectious diseases.
According to a post on Protein Sciences’ website, Flublok supply is limited for the 2012-2013 influenza season. The company expects to have full production available during the 2013-2014 influenza season. The makeup of that vaccine will be determined in the spring by health officials.
For the 10-page package insert on Flublok, click here.
The shot, which contains three times the active ingredient as compared with many other flu vaccines, is administered to a patient’s upper arm. Subsequent side effects are similar to that of flu shots currently on the market. In an effectiveness study of about 4,500 people, Flublok was about 44.6% effective versus placebo against all circulating influenza strains, not just the strains that matched the strains included in the vaccine.
Flublok is approved for the prevention of seasonal influenza in people 18 through 49 years of age. Flublok contains three full-length, recombinant HA proteins to help protect against two influenza virus A strains, H1N1 and H3N2, and one influenza virus B strain. Protein Sciences is also working on a pandemic vaccine Panblok, which is designed to protect against pandemic influenza in partnership with the Biomedical Advanced Research and Development Authority, a division of the U.S. Department of Health and Human Services.
Flublok has a shelf life of 16 weeks from the date of manufacture. Healthcare providers should check the expiration date before administering Flublok.
In anticipation of the approval, in November Protein Sciences leased a production facility from Pfizer at the Pearl River Campus in Rockland County, N.Y.
Find us on Facebook for more information on drug store news, insights and products.